Key clinical point: Psoriasis patients on biologic therapy also showed significant improvement in coronary inflammation after 1 year.

Major finding: The median perivascular fat attenuation index for patients treated with biologics decreased from a median of –71.22 Hounsfield units at baseline to a median of –76.09 Hounsfield units at 1 year (P less than .001).

Study details: The data come from a prospective cohort study of 134 adults with moderate to severe psoriasis.

Disclosures: The study was funded by the National Institutes of Health, several research foundations, Elsevier, Colgate-Palmolive, and Genentech. Dr. Elnabawi had no financial conflicts to disclose; several coauthors reported relationships with multiple companies. One coauthor disclosed a pending and licensed patent to a novel tool for cardiovascular risk stratification based on the CT attenuation of perivascular tissue (OxScore) and a pending and licensed patent to perivascular texture index.